C Gilfrich1, H Leicht2, C Fahlenbrach3, E Jeschke2, G Popken4, J U Stolzenburg5, L Weißbach6, C Zastrow7, C Günster2. 1. Department of Urology, St. Elisabeth Klinikum Straubing, Straubing, Germany. 2. Research Institute of the Local Health Care Funds (WIdO), Berlin, Germany. 3. Federal Association of the Local Health Care Funds (AOK), Berlin, Germany. 4. Department of Urology, Ernst von Bergmann Hospital, Potsdam, Germany. 5. Department of Urology, University of Leipzig, Leipzig, Germany. 6. Foundation Men's Health (Stiftung Männergesundheit), Berlin, Germany. 7. Medical Review Board of the Social Health Insurance Funds, Hannover, Germany.
Abstract
BACKGROUND: Little real-world data is available on the comparison of different methods in surgery for lower urinary tract symptoms due to benign prostatic obstruction in terms of complications. The objective was to evaluate the proportions of TURP, open prostatectomy (OP) and laser-based surgical approaches over time and to analyse the effect of approach on complication rates. METHODS: Using data of the German local healthcare funds (Allgemeine Ortskrankenkassen (AOK)), we identified 95 577 cases with a primary diagnosis of hyperplasia of prostate who received TURP, laser vaporisation (LVP), laser enucleation (LEP) of the prostate or OP between 2008 and 2013. Univariable logistic regression was used to analyse proportions of surgical approach over time, and the effect of surgical method on outcomes was analysed by means of multivariable logistic regression. RESULTS: The proportion of TURP decreased from 83.4% in 2008 to 78.7% in 2013 (P<0.001). Relative to TURP and adjusting for age, co-morbidities, AOK hospital volume, year of surgery and antithrombotic medication, OP had increased mortality (odds ratio (OR) 1.47, P<0.05), transfusions (OR 5.20, P<0.001) and adverse events (OR 2.17, P<0.001), and lower re-interventions for bleeding (OR 0.75, P<0.001) and long-term re-interventions (OR 0.55, P<0.001). LVP carried a lower risk of transfusions (OR 0.57, P<0.001) and re-interventions for bleeding (OR 0.76, P<0.001), but a higher risk of long-term re-interventions (OR 1.43, P<0.001). LEP had increased re-interventions for bleeding (OR 1.35, P<0.01). Complications were also dependent on age and co-morbidity. Limitations include the lack of clinical information and functional results. CONCLUSIONS: OP has the greatest risks of complication despite a low re-intervention rate. LVP demonstrated favourable results for transfusion and bleeding, but increased long-term re-interventions compared with TURP, while LEP showed increased re-interventions for bleeding. Findings support a careful indication and choice of method for surgery for LUTS, taking age and co-morbidities into account.
BACKGROUND: Little real-world data is available on the comparison of different methods in surgery for lower urinary tract symptoms due to benign prostatic obstruction in terms of complications. The objective was to evaluate the proportions of TURP, open prostatectomy (OP) and laser-based surgical approaches over time and to analyse the effect of approach on complication rates. METHODS: Using data of the German local healthcare funds (Allgemeine Ortskrankenkassen (AOK)), we identified 95 577 cases with a primary diagnosis of hyperplasia of prostate who received TURP, laser vaporisation (LVP), laser enucleation (LEP) of the prostate or OP between 2008 and 2013. Univariable logistic regression was used to analyse proportions of surgical approach over time, and the effect of surgical method on outcomes was analysed by means of multivariable logistic regression. RESULTS: The proportion of TURP decreased from 83.4% in 2008 to 78.7% in 2013 (P<0.001). Relative to TURP and adjusting for age, co-morbidities, AOK hospital volume, year of surgery and antithrombotic medication, OP had increased mortality (odds ratio (OR) 1.47, P<0.05), transfusions (OR 5.20, P<0.001) and adverse events (OR 2.17, P<0.001), and lower re-interventions for bleeding (OR 0.75, P<0.001) and long-term re-interventions (OR 0.55, P<0.001). LVP carried a lower risk of transfusions (OR 0.57, P<0.001) and re-interventions for bleeding (OR 0.76, P<0.001), but a higher risk of long-term re-interventions (OR 1.43, P<0.001). LEP had increased re-interventions for bleeding (OR 1.35, P<0.01). Complications were also dependent on age and co-morbidity. Limitations include the lack of clinical information and functional results. CONCLUSIONS: OP has the greatest risks of complication despite a low re-intervention rate. LVP demonstrated favourable results for transfusion and bleeding, but increased long-term re-interventions compared with TURP, while LEP showed increased re-interventions for bleeding. Findings support a careful indication and choice of method for surgery for LUTS, taking age and co-morbidities into account.
Authors: Stavros Gravas; Alexander Bachmann; Oliver Reich; Claus G Roehrborn; Peter J Gilling; Jean De La Rosette Journal: BJU Int Date: 2011-04 Impact factor: 5.588
Authors: Bilal I Chughtai; Vannita Simma-Chiang; Richard Lee; Abby Isaacs; Alexis E Te; Steven A Kaplan; Art Sedrakyan Journal: J Endourol Date: 2014-12-11 Impact factor: 2.942
Authors: Sascha A Ahyai; Peter Gilling; Steven A Kaplan; Rainer M Kuntz; Stephan Madersbacher; Francesco Montorsi; Mark J Speakman; Christian G Stief Journal: Eur Urol Date: 2010-06-11 Impact factor: 20.096
Authors: Richard Naspro; Alexander Bachmann; Peter Gilling; Rainer Kuntz; Stephan Madersbacher; Francesco Montorsi; Oliver Reich; Christian Stief; Ivano Vavassori Journal: Eur Urol Date: 2009-04-03 Impact factor: 20.096
Authors: Jean-Nicolas Cornu; Sascha Ahyai; Alexander Bachmann; Jean de la Rosette; Peter Gilling; Christian Gratzke; Kevin McVary; Giacomo Novara; Henry Woo; Stephan Madersbacher Journal: Eur Urol Date: 2014-06-25 Impact factor: 20.096
Authors: David R Anderson; Gian Paolo Morgano; Carole Bennett; Francesco Dentali; Charles W Francis; David A Garcia; Susan R Kahn; Maryam Rahman; Anita Rajasekhar; Frederick B Rogers; Maureen A Smythe; Kari A O Tikkinen; Adolph J Yates; Tejan Baldeh; Sara Balduzzi; Jan L Brożek; Itziar Etxeandia- Ikobaltzeta; Herman Johal; Ignacio Neumann; Wojtek Wiercioch; Juan José Yepes-Nuñez; Holger J Schünemann; Philipp Dahm Journal: Blood Adv Date: 2019-12-10
Authors: Rano Matta; Erind Dvorani; Christopher Wallis; Amanda Hird; Joseph LaBossiere; Girish Kulkarni; Ronald Kodama; Lesley Carr; Sidney B Radomski; Refik Saskin; Sender Herschorn; Robert K Nam Journal: BMJ Open Date: 2019-12-30 Impact factor: 2.692